Mercer Global Advisors’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Mercer Global Advisors’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,325	Closed	-$39K	–	2065
2023 Q1	$39K	Sell	5,325 -94	-2%	-$799	﹤0.01%	1879
2022 Q4	$36K	Buy	5,419 +94	+2%	+$824	﹤0.01%	1883
2022 Q3	$54K	Hold	5,325	–	–	﹤0.01%	1764
2022 Q2	$65K	Buy	5,325 +4,566	+602%	+$72.2K	﹤0.01%	1757
2022 Q1	$16K	Buy	759 +23	+3%	+$796	﹤0.01%	1859
2021 Q4	$44K	Sell	736 -600	-45%	-$44.9K	﹤0.01%	1760
2021 Q3	$125K	Hold	1,336	–	–	﹤0.01%	1670
2021 Q2	$221K	Hold	1,336	–	–	﹤0.01%	1523
2021 Q1	$257K	Buy	+1,336	New	+$333K	﹤0.01%	1384

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mercer Global Advisors's TLIS Position: Q2 2023 in Review

Mercer Global Advisors sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2023, closing a stake of 5,325 shares — an estimated $39K sold.

Mercer Global Advisors first reported a position in TLIS in Q1 2021 and held it in 9 quarters. The position peaked at $257K in Q1 2021. 22 funds tracked by Wall St. Rank hold TLIS as of Q2 2023.

Mercer Global Advisors reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
Mercer Global Advisors sold 5,325 Talis Biomedical Corporation Common Stock shares in Q2 2023, an estimated $39K.
Mercer Global Advisors first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 9 quarters.
Mercer Global Advisors's Talis Biomedical Corporation Common Stock position peaked at $257K in Q1 2021.
22 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2023.

Based on Mercer Global Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.